CD34 and neoplasm: The expression level of CD34, a surface marker of proliferating vascular endothelial cells, was significantly decreased inside tumor tissue infected by ST/TRAIL-RGD4C-ES compared to other treatment groups (Figure 7; Supplementary Figure S7B).